Evidence-based diuretics: focus on chlorthalidone and indapamide

Area of Science:

• Pharmacology and Therapeutics
• Cardiovascular Medicine

Background:

• Thiazide and thiazide-like diuretics are primary treatments for hypertension.
• Hydrochlorothiazide (HCTZ) is widely prescribed, despite limited evidence of morbidity and mortality benefits compared to placebo or control.
• Chlorthalidone (CTD) and indapamide (IDP) have demonstrated significant cardiovascular benefits.

Purpose of the Study:

• To compare the evidence supporting hydrochlorothiazide (HCTZ) against chlorthalidone (CTD) and indapamide (IDP) in hypertension management.
• To advocate for guideline changes recommending CTD and IDP as preferred thiazide-like diuretics.

Main Methods:

• Review of pharmacological differences between HCTZ, CTD, and IDP.
• Analysis of clinical trial data evaluating the efficacy and safety of these diuretics.
• Examination of reported side effects associated with each agent.

Main Results:

• HCTZ lacks robust evidence for reducing morbidity and mortality as monotherapy, unlike CTD and IDP.
• Despite evidence gaps, HCTZ remains more frequently prescribed than CTD or IDP.
• Significant pharmacological and clinical differences exist between HCTZ, CTD, and IDP.

Conclusions:

• Hypertension guidelines should be updated to recommend indapamide (IDP) and chlorthalidone (CTD) as first-choice thiazide-like diuretics, aligning with NICE recommendations.
• The evidence supports prioritizing CTD and IDP over HCTZ due to superior demonstrated clinical outcomes.